作者: I. Macintyre , M.I. Whitehead , L.M. Banks , J.C. Stevenson , S.J. Wimalawansa
DOI: 10.1016/S0140-6736(88)91712-6
关键词:
摘要: Abstract A 2-year randomised pilot study was conducted in 70 patients to see whether the osteoclast-inhibiting effect of calcitonin would reduce postmenopausal vertebral bone loss. An oestradiol-treated group included as a positive control since oestrogens are known be effective. Calcitonin reduced loss doses above 250 ug human (50 international units) week, and at this dose effective oestradiol.